Editorial Comments
Anti-IL-1 Therapy in Management of Patients with Behçet’s Disease During the COVID-19 Pandemic
1Rheumatology Clinic, Atatürk State Hospital, Aydın, Turkey
2Medical School Student, Lokman Hekim University Faculty of Medicine, Ankara, Turkey
3Division of Rheumatology and Immunology, Department of Physical Medicine and Rehabilitation, Sakarya University Faculty of Medicine, Sakarya, Turkey
2Medical School Student, Lokman Hekim University Faculty of Medicine, Ankara, Turkey
3Division of Rheumatology and Immunology, Department of Physical Medicine and Rehabilitation, Sakarya University Faculty of Medicine, Sakarya, Turkey
J Clin Pract Res 2022; 44(2): 121-122 DOI: 10.14744/etd.2021.63139
Keywords: Anti-IL-1, Behçet’s disease, COVID-19, Treatment